Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatic Portal System01:21

Hepatic Portal System

4.2K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
4.2K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.6K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PDE4 inhibitor mitigates activated CD8+ T cells through NF-κB signaling in Behçet's syndrome.

Frontiers in immunology·2026
Same author

Long-term outcomes and prognosis of mixed cryoglobulinaemia: a European multicentre study of 1294 patients.

Rheumatology (Oxford, England)·2026
Same author

Treat-to-target in Behçet syndrome.

Nature reviews. Rheumatology·2026
Same author

French recommendations for the use of imaging in giant cell arteritis.

Joint bone spine·2026
Same author

Clonal haematopoiesis of indeterminate potential and relapses in patients with GCA.

Rheumatology (Oxford, England)·2026
Same author

Takayasu arteritis phenotypes and outcomes: A data-driven cluster analysis from a large international cohort.

Journal of autoimmunity·2026

Related Experiment Video

Updated: Nov 27, 2025

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.6K

Hepatitis C virus-related vasculitis.

Gonçalo Boleto1, Matheus Vieira1, David Saadoun2

  • 1AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France; Centre de Référence des Maladies Auto-Immunes et Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose, France.

Clinics and Research in Hepatology and Gastroenterology
|December 3, 2020
PubMed
Summary

Cryoglobulinemic vasculitis (CryoVas) linked to Hepatitis C virus (HCV) infection shows high mortality. New direct-acting antivirals (DAAs) improve outcomes, but severe cases still need better treatments.

Keywords:
CryoglobulinemiaHepatitis C virusPathophysiologyTreatmentVasculitis

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.1K
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

887

Related Experiment Videos

Last Updated: Nov 27, 2025

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.6K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.1K
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

887

Area of Science:

  • Immunology
  • Rheumatology
  • Hepatology

Background:

  • Cryoglobulinemic vasculitis (CryoVas) is a systemic vasculitis associated with immune complex deposition.
  • Hepatitis C virus (HCV) infection is a primary driver of CryoVas, significantly increasing mortality.
  • Current management faces challenges in severe and refractory cases.

Purpose of the Study:

  • To review the current understanding of HCV-associated CryoVas.
  • To highlight the impact of novel antiviral therapies on CryoVas management.
  • To identify unmet needs in treating severe and refractory HCV-related CryoVas.

Main Methods:

  • Literature review of CryoVas pathogenesis and treatment.
  • Analysis of outcomes with direct-acting antivirals (DAAs) and B-cell depletion therapies.
  • Synthesis of current therapeutic strategies and identification of research gaps.

Main Results:

  • Direct-acting antivirals (DAAs) achieve high sustained virological response rates in HCV, improving CryoVas prognosis.
  • Rituximab and other B-cell depleting agents are key for severe/refractory HCV-associated CryoVas.
  • Despite advances, significant challenges remain in managing complex CryoVas cases.

Conclusions:

  • HCV-associated CryoVas management has been revolutionized by DAAs.
  • Therapeutic strategies for severe and refractory CryoVas require further development.
  • Addressing unmet needs is crucial for improving long-term outcomes in CryoVas patients.